体内有低麻醉阿托品的my鸦片管理

H. Kaymak, Birte Graff, F. Schaeffel, A. Langenbucher, B. Seitz, Hartmut Schwahn
{"title":"体内有低麻醉阿托品的my鸦片管理","authors":"H. Kaymak, Birte Graff, F. Schaeffel, A. Langenbucher, B. Seitz, Hartmut Schwahn","doi":"10.54352/dozv.mnfd4523","DOIUrl":null,"url":null,"abstract":"Purpose. The aim of the study was to determine the thera­ peutic effect of low­dose atropine for inhibiting myopia pro­ gression in clinical practice outside of controlled clinical trials. Material and Methods. We performed a retrospective analysis on data collected on a regular basis (refraction, axial length) pertaining to 79 children treated with atropine and 100 un­ treated children over an observation period of 12 months. Results. Our findings show that myopia progressed in both groups with highly variable progression rates. A two­way ANOVA for age and atropine effects on axial length growth revealed that axial length growth rates decline with age (p < 0.0001) and that atropine has a significant inhibitory effect on axial length growth (p < 0.0015) independent of age. However, this effect showed only a 0.08 mm inhibition rate per year (28 %) as compared to the average growth rate in the untreated children, meaning that its magnitude is quite small. Furthermore, the effect of atropine on the refractive power was not significant. Conclusion. We found that, in this clinical setting, the effects of atropine were not distinctive and of only minor clinical relevance. The results of this study show that the beneficial effects of a treatment with 0.01% atropine eye drops may not be apparent in every individual case, information that should be communicated to the parents of myopic children and general ophthalmologists. Keywords axial length, children, atropine, myopia, controlling myopia","PeriodicalId":347784,"journal":{"name":"Optometry &amp; Contact Lenses","volume":"11 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Myopie-Managementmit niedrig dosiertem Atropin in der klinischen Praxis \",\"authors\":\"H. Kaymak, Birte Graff, F. Schaeffel, A. Langenbucher, B. Seitz, Hartmut Schwahn\",\"doi\":\"10.54352/dozv.mnfd4523\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose. The aim of the study was to determine the thera­ peutic effect of low­dose atropine for inhibiting myopia pro­ gression in clinical practice outside of controlled clinical trials. Material and Methods. We performed a retrospective analysis on data collected on a regular basis (refraction, axial length) pertaining to 79 children treated with atropine and 100 un­ treated children over an observation period of 12 months. Results. Our findings show that myopia progressed in both groups with highly variable progression rates. A two­way ANOVA for age and atropine effects on axial length growth revealed that axial length growth rates decline with age (p < 0.0001) and that atropine has a significant inhibitory effect on axial length growth (p < 0.0015) independent of age. However, this effect showed only a 0.08 mm inhibition rate per year (28 %) as compared to the average growth rate in the untreated children, meaning that its magnitude is quite small. Furthermore, the effect of atropine on the refractive power was not significant. Conclusion. We found that, in this clinical setting, the effects of atropine were not distinctive and of only minor clinical relevance. The results of this study show that the beneficial effects of a treatment with 0.01% atropine eye drops may not be apparent in every individual case, information that should be communicated to the parents of myopic children and general ophthalmologists. Keywords axial length, children, atropine, myopia, controlling myopia\",\"PeriodicalId\":347784,\"journal\":{\"name\":\"Optometry &amp; Contact Lenses\",\"volume\":\"11 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Optometry &amp; Contact Lenses\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.54352/dozv.mnfd4523\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Optometry &amp; Contact Lenses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54352/dozv.mnfd4523","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的。本研究的目的是在对照临床试验之外确定低剂量阿托品在临床实践中抑制近视进展的治疗效果。材料和方法。我们对79名接受阿托品治疗的儿童和100名未接受阿托品治疗的儿童进行了为期12个月的定期收集的数据(屈光、眼轴长度)进行了回顾性分析。结果。我们的研究结果表明,两组患者的近视进展率变化很大。年龄和阿托品对轴长生长影响的双向方差分析显示,轴长生长速率随年龄的增长而下降(p < 0.0001),阿托品对轴长生长有显著的抑制作用(p < 0.0015),与年龄无关。然而,与未经治疗的儿童的平均生长速度相比,这种效果每年仅显示0.08毫米的抑制率(28%),这意味着其幅度相当小。此外,阿托品对折光功率的影响不显著。结论。我们发现,在这种临床情况下,阿托品的效果不明显,只有轻微的临床相关性。本研究结果表明,0.01%阿托品滴眼液治疗的有益效果可能并非在每个病例中都很明显,这一信息应与近视儿童的父母和普通眼科医生沟通。关键词眼轴长度;儿童;阿托品
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Myopie-Managementmit niedrig dosiertem Atropin in der klinischen Praxis 
Purpose. The aim of the study was to determine the thera­ peutic effect of low­dose atropine for inhibiting myopia pro­ gression in clinical practice outside of controlled clinical trials. Material and Methods. We performed a retrospective analysis on data collected on a regular basis (refraction, axial length) pertaining to 79 children treated with atropine and 100 un­ treated children over an observation period of 12 months. Results. Our findings show that myopia progressed in both groups with highly variable progression rates. A two­way ANOVA for age and atropine effects on axial length growth revealed that axial length growth rates decline with age (p < 0.0001) and that atropine has a significant inhibitory effect on axial length growth (p < 0.0015) independent of age. However, this effect showed only a 0.08 mm inhibition rate per year (28 %) as compared to the average growth rate in the untreated children, meaning that its magnitude is quite small. Furthermore, the effect of atropine on the refractive power was not significant. Conclusion. We found that, in this clinical setting, the effects of atropine were not distinctive and of only minor clinical relevance. The results of this study show that the beneficial effects of a treatment with 0.01% atropine eye drops may not be apparent in every individual case, information that should be communicated to the parents of myopic children and general ophthalmologists. Keywords axial length, children, atropine, myopia, controlling myopia
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信